We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Evaluate Safety, Tolerability and Efficacy of Lytixar™ (LTX-109) on Uncomplicated, Gram-positive, Skin Infection

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01223222
Recruitment Status : Completed
First Posted : October 18, 2010
Last Update Posted : February 16, 2011
Sponsor:
Information provided by:
Lytix Biopharma AS

Brief Summary:

The purpose of this study is to evaluate the safety and tolerability of Lytixar™ applied topically to uncomplicated skin infections.

Three dose levels of Lytixar™ (1%, 2% and 5%) versus placebo will be tested.


Condition or disease Intervention/treatment Phase
Gram-positive, Skin Infections Mild Eczema/Dermatoses Atopic Dermatitis Drug: LTX-109 Phase 2

Detailed Description:
Treatment of uncomplicated, Gram-positive, skin infection may include application of antiseptics and desiccants, but most importantly topical antibiotics. Guidance on the use of antimicrobial therapies has been published, poor prescribing practices still exist which facilitate the development of bacterial strains resistant to available therapy. The issue of antimicrobial resistance is particularly important for Gram-positive cocci such as Staphylococcus aureus and Streptococcus pyogenes. Methicillin-resistant Staphylococcus aureus (MRSA) has been a problem for many years in the hospital setting, more recently community acquired MRSA (CA-MRSA) has emerged posing additional challenges to physicians managing skin infection. The medicinal product under development, Lytixar™, is a synthetic antimicrobial peptidomimetic agent with a membrane lysing mode of action. Lytixar™ has demonstrated activity against several Gram-positive and Gram-negative bacteria in vitro. The compound appears to be equally effective against antibiotic-resistant species such as methicillin resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococci (VRE) and multi-resistant Pseudomonas isolates. The novel membrane lysing mode of action may result in a lower propensity to the development of resistance and to date Lytixar™ demonstrates no in vitro target-specific cross-resistance with other classes of antibiotics.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 24 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomised, Double-blind, Placebo-controlled, Phase IIa Pilot Study to Evaluate the Safety, Tolerability and Efficacy of Lytixar™ (LTX-109) in Patients With Uncomplicated, Gram-positive, Skin Infection
Study Start Date : September 2010
Actual Primary Completion Date : February 2011
Actual Study Completion Date : February 2011

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Placebo Comparator: 1% Lytixar™
6 subjects will be treated with Lytixar™ and 2 will be treated with vehicle (placebo).
Drug: LTX-109
Topical administration. 3 times daily. 5 days.

Active Comparator: 2% Lytixar™
6 subjects will be treated with Lytixar™ and 2 will be treated with vehicle (placebo).
Drug: LTX-109
Topical administration. 3 times daily. 5 days.

Active Comparator: 5% Lytixar™
6 subjects will be treated with Lytixar™ and 2 will be treated with vehicle (placebo).
Drug: LTX-109
Topical administration. 3 times daily. 5 days.




Primary Outcome Measures :
  1. To determine the safety and local tolerability of topically administered Lytixar™ in patients with uncomplicated, Gram-positive, skin infection. [ Time Frame: After topical treatment 3 times per day 5 days ]
    Tolerability and safety will be measured at Day 3, the end of treatment visit Day 7 and follow-up visits Day 14, and 21.


Secondary Outcome Measures :
  1. To assess the clinical and microbiological response to Lytixar™ in patients with uncomplicated, Gram-positive, skin infection. And to determine the extent of systemic absorption of Lytixar™. [ Time Frame: Topical treatment 3 times daily for 5 days. ]
    Clinical outcome, changes in the Skin Infection Rating Scale (SIRS) scores from Baseline, and Bacteriological success, recurrence, failure or evaluability will be assessed at Day 3, end of treatment visit Day 7 and follow-up visits Day 14 and 21.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male and female patients between the ages of 18 and 65, inclusive.
  • Diagnosis of uncomplicated, Gram-positive, skin infection. This may include patients with mild eczema/dermatoses such as atopic dermatitis.
  • Gram-positive organisms determined at Baseline (Day 1) which in the opinion of the investigator are causative for infection of the lesion(s).

Candidate for treatment with topical antibacterial therapy:

  • area to be treated ≤100 cm2
  • SIRS score of at least 8 for the area of study medication application

    • Female patients of child bearing potential and male patients with female partners of child-bearing potential must be willing to use an adequate barrier form of contraception, (i.e., diaphragm or condom with spermicidal agent) prior to entry into the study and for two weeks following the completion of all follow-up procedures. Hormonal contraception or hormonal IUDs alone are not considered to be acceptable forms of contraception.
    • Provision of signed and dated written informed consent by the patient.
    • Patient's medical condition is stable, with no other clinically significant abnormalities as determined by the investigator.
    • Patients must be able to understand the written patient information and the consent form, and be willing to return to the study site for follow up visits, comply with requirements, instructions and restrictions of the study as listed in the informed consent form.

Exclusion Criteria:

  • Moderate to Severe dermatoses including but not limited to psoriasis, atopic dermatitis or eczema.
  • Secondarily-infected animal/human bite, puncture wound or abscess.
  • Chronic ulcerative lesions.
  • Bacterial skin infection which, due to the area, depth or severity, in the opinion of the investigator, cannot be appropriately treated by a topical antibiotic.
  • More than one type of infected lesion.
  • Surgical intervention is required for treatment of the infection prior to enrolment in the study, or such intervention is likely to be required during the course of the study.
  • Application of any topical pharmaceutical agent (including but not limited to, corticosteroids, antibacterials, antiseptics or antifungal agents) directly to the infected wound/lesion(s), within 72 hours prior to study entry.
  • Systemic signs or symptoms of infection (such as fever).
  • Treatment for one or more days with a systemic antibacterial agent within 72 hours of study entry.
  • Ongoing treatment with systemic corticosteroids at a dose of >0.125mg/kg per day of prednisone (or the equivalent).
  • Known, pre-existing or serious underlying disease that could be imminently life-threatening.
  • Pregnancy or ongoing lactation.
  • Participation in any study using an investigational drug or device during the previous 30 days prior to entering the study.
  • Significant ongoing or history of drug or alcohol abuse which in the opinion of the investigator makes the patient unsuitable for enrolment.
  • Known allergic reactions or hypersensitivity of significant severity in general and specifically to any component of the study medication.
  • Current or history of significant hepatic, renal, endocrine, cardiac, nervous, psychiatric, gastrointestinal, pulmonary, haematological, or metabolic disorder that is not in a stable condition. Malignancy <5 years since last treatment (resolved basal cell carcinoma is permitted).
  • Current or history of any significant disease or condition known to interfere with the absorption, distribution, metabolism or excretion of drugs.
  • Other unspecified reasons that, in the opinion of the investigator make the Patient unsuitable for enrolment.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01223222


Locations
Layout table for location information
Hungary
Debreceni Egyetem Orvos-és Egészségtudományi
Debrecen, Hungary, 4032
Miskolci Semmelweis Ignác Egészegügyi Központ és
Miskolc, Hungary, 3529
Pécsi Tudományegyetem általános Orvostudom´nyi Centum
Pécs, Hungary, 7624
Szeged Univesrity Hospital
Szeged, Hungary, 6720
Sponsors and Collaborators
Lytix Biopharma AS
Investigators
Layout table for investigator information
Principal Investigator: Lajos Kemeny, DSc, Prof St. George Albert Clinic Zeged University Hospital
Layout table for additonal information
Responsible Party: Wenche Marie Olsen, Director of Development, Infectious Diseases, Lytix Biopharma AS
ClinicalTrials.gov Identifier: NCT01223222    
Other Study ID Numbers: C10-109-03
First Posted: October 18, 2010    Key Record Dates
Last Update Posted: February 16, 2011
Last Verified: February 2011
Keywords provided by Lytix Biopharma AS:
Uncomplicated skin infections
Impetigo
Gram-negative
Diagnosis of uncomplicated, Gram-positive, skin infection. This may include patients with mild eczema/dermatoses such as atopic dermatitis.
Gram-positive organisms which in the opinion of the investigator are causative for infection of the lesion(s),
Additional relevant MeSH terms:
Layout table for MeSH terms
Infections
Communicable Diseases
Cellulitis
Skin Diseases, Infectious
Dermatitis, Atopic
Dermatitis
Eczema
Skin Diseases
Disease Attributes
Pathologic Processes
Skin Diseases, Genetic
Genetic Diseases, Inborn
Skin Diseases, Eczematous
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Suppuration
Connective Tissue Diseases
Inflammation